Tissue distribution and tumour localization of 99m-technetium-labelled liposomes in cancer patients.
The possible use of liposomes (phospholipid vesicles) to direct cytotoxic drugs to tumours has led us to investigate the tissue localization of i.v. injected 99m-Tc-labelled liposomes in cancer patients. Twenty mg or 300 mg doses of liposomal lipid (7:2:1 molar ratio of phosphatidylcholine : cholesterol : phosphatidic acid) were used in a study of 13 patients with advanced cancer and one with polycythaemia rubra vera (PRV). In all cases except the patient with PRV the major site of uptake of the label was the liver and spleen. In the patient with PRV the liver uptake was greatly reduced and the major site of uptake was found in regions corresponding to marrow. With the exception of one patient with a primary hepatoma, there was no significant tumour uptake of the label.
D002784:Cholesterol / Q000378:metabolism; D005260:Female; D006801:Humans; D008081:Liposomes / Q000378:metabolism*; D008099:Liver / Q000378:metabolism; D008297:Male; D009369:Neoplasms / Q000378:metabolism*; D010712:Phosphatidic Acids / Q000378:metabolism; D010713:Phosphatidylcholines / Q000378:metabolism; D011087:Polycythemia Vera / Q000378:metabolism; D013154:Spleen / Q000378:metabolism; D013667:Technetium / Q000378:metabolism; D014018:Tissue Distribution
D008081:Liposomes; D010712:Phosphatidic Acids; D010713:Phosphatidylcholines; D013667:Technetium; D002784:Cholesterol